# Rain Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rain-therapeutics

- Industry: Biotechnology
- Headquarters: Newark, US
- Website: www.rainthera.com
- Total disclosed funding: $91M
- Latest round: Series B (Sep 2, 2020)
- Investors on record: 8

## About

Rain Therapeutics Inc. is a US-based biotechnology company focused on the development and commercialization of innovative oncology therapies aimed at addressing unmet medical needs in cancer treatment.Founded in 2017 in Newark, US, Rain Therapeutics Inc. specializes in oncological therapeutics. The firm has completed five deals, with its most recent funding event occurring on April 22, 2021, during a PIPE round where it raised USD 50.00 mn from various investors including Adage Capital Management and BVF Partners. The company's CEO is Avanish Vellanki, one of the co-founders, whose previous entrepreneurial experience contributes to the firm's strategic direction.Rain Therapeutics Inc. focuses on developing and commercializing innovative therapies aimed at addressing unmet medical needs in oncology. Their primary offerings include targeted therapeutics specifically designed to inhibit cancer cell growth through unique mechanisms of action. These products target various forms of cancer, including solid tumors, with the goal of improving patient outcomes while minimizing side effects associated with traditional chemotherapies. The company caters to a diverse customer base, including hospitals, oncology clinics, and research institutions primarily in North America and select markets in Europe.Rain Therapeutics Inc. generates revenue through direct sales and partnerships with healthcare providers. The company engages in B2B collaborations with healthcare facilities to supply its therapeutics, establishing recurring transactions based on patient needs. While exact pricing structures for its flagship products are proprietary, the company emphasizes the value of its therapies in oncology treatment, supported by contractual agreements detailing pricing and delivery terms. Revenue is further enhanced through potential collaborations with pharmaceutical firms in research and development initiatives.Rain Therapeutics Inc. is planning to enhance its product offerings and expand into new markets. The company intends to utilize proceeds from its most recent funding round, which raised USD 50.00 mn in November 2022, for clinical development of its pipeline candidates and preparation for commercial launches. Rain Therapeutics aims to enter additional geographic regions targeting broader access to its therapies by the end of 2023. This strategic focus reflects the company's commitment to advancing cancer treatment options and improving the quality of life for patients.

## Funding rounds

- Series B, Sep 2, 2020, $73M — BVF Partners, Cormorant Asset Management, Perceptive Advisors, Boxer Capital, Janus Henderson Investors, Samsara BioCapital, Logos Capital
- Series A, Apr 19, 2018, $18M — Auckland Uniservices Limited, BVF Partners, Perceptive Advisors

## Investors

- Auckland Uniservices Limited — Series A
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A, Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A, Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Janus Henderson Investors — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B